Bristol-Myers Squibb Company (BMY)

Jefferies Group analyst J. Holford now expects that the biopharmaceutical company will earn $2.86 per share for the year, up from their previous estimate of $2.79.

With a total market value of $0, Bristol-Myers Squibb Co has price-earnings ratio of 20.16 with a one year low of $46.01 and a one year high of $77.12.

Now, the FactSet Research estimate calls for Q1 2017 earnings of US$0.73. Bristol-Myers Squibb had a net margin of 22.94% and a return on equity of 31.39%. The business had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.14 billion.

Its sales stood at -1.80% a year on average in the period of last five years. Bristol-Myers Squibb's quarterly revenue was up 22.3% on a year-over-year basis. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/04/14/leerink-swann-analysts-raise-earnings-estimates-for-bristol-myers-squibb-co-bmy.html. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & worldwide copyright and trademark legislation. Moving average strategies are also popular and can be tailored to any time frame, suiting both long term investors and short-term traders. Analysts anticipate that Bristol-Myers Squibb Co will post $2.80 earnings per share for the current fiscal year. BMO Capital Markets reiterated a "market perform" rating and issued a $45.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 4th. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned "Outperform" rating by Credit Suisse on Monday, May 9.

U.S. based company, Bristol-Myers Squibb Company (BMY)'s latest closing price distance was at -7.48% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -2.61% and -3.46% compared with the 20 Day Moving Average. ABR value is precisely based on brokerage recommendations, where out of 13 brokerage recommendations 6 rate Bristol-Myers Squibb Co (NYSE:BMY) stock a Strong Buy, 1 rate the stocks of the company a Buy, 6 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Also, the current price highlights a discount of 36.25% to analysts' high consensus price target.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at 52.99 on Thursday.

Turning to Unit Corporation (NYSE:UNT), its shares were trading at $24.22 a gain of $0.34, on the trading floor. The company's 50-day moving average is $55.74 and its 200-day moving average is $54.67. The company has a market capitalization of $88.64 billion, a price-to-earnings ratio of 20.00 and a beta of 1.00.

More news: German investigators check further claim for Dortmund attack

Several research analysts have recently weighed in on BMY shares. Security Asset Management's holdings in Bristol-Myers Squibb were worth $662,000 at the end of the most recent quarter. With 1.92M avg volume, 4 days are for Nielsen Holdings Plc (NYSE:NLSN)'s short sellers to cover NLSN's short positions. 1 Month Ago, shares have been suggested as BUY from 10 and 1 issued SELL signal for the company's stock.12 told as a HOLD the stock. Sabby Management stated it has 0.98% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). CA boosted its stake in shares of Bristol-Myers Squibb by 21.0% in the third quarter.

Rhenman & Partners Asset Management Ab decreased Kite Pharma Inc (NASDAQ:KITE) stake by 10,000 shares to 80,000 valued at $3.59 million in 2016Q4. Webster Bank N.A. now owns 43,573 shares of the biopharmaceutical company's stock valued at $2,349,000 after buying an additional 570 shares in the last quarter.

11/07/2016 - Bristol-Myers Squibb Company had its "buy" rating reiterated by analysts at Citigroup. They now have a Dollars 60 price target on the stock.

The number of shares now held by investors is 1.65 Billion. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 92,405 shares of the company's stock in a transaction dated Monday, March 6th. The stock was trading on below-average volume. Following the completion of the sale, the executive vice president now owns 488,063 shares in the company, valued at $27,829,352.26. The disclosure for this purchase can be found here.

Bristol-Myers Squibb Co (NYSE:BMY) performance over the past one year plunged -18.65% whereas its year to date (YTD) performance indicated a bearish trend of -8.08%.

The firm also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Friday, April 7th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.95%.

Edition: